Screening of well-established drugs targeting cancer metabolism: Reproducibility of the efficacy of a highly effective drug combination in mice

Investigational New Drugs

Volumn 30, Issue 4, 2012, Pages 1331-1342

  Abolhassani, Mohammad ^a   Guais, Adeline ^a   Sanders, Edward ^a   Campion, Frédéric ^a   Fichtner, Iduna ^b   Bonte, Jacques ^a   Baronzio, Gianfranco ^c   Fiorentini, Giammaria ^d   Israël, Maurice ^a   Schwartz, Laurent ^e,f  

^a Experimental Pharmacology and Oncology ^*  (France)

^b Experimental Pharmacology and Oncology EPO GmbH   (Germany)

^c Centro Medico Kines   (Italy)

^d S Giuseppe Hospital   (Italy)

^e ECOLE POLYTECHNIQUE   (France)

^f RAYMOND POINCARÉ HOSPITAL   (France)

Author keywords

Hydroxycitrate; Lipoic acid; Metabolic enzymes; Octreotide; Screening

Indexed keywords

ACETAZOLAMIDE; ALBENDAZOLE; AMOBARBITAL; AMRINONE; BETAINE; CISPLATIN; DICHLOROACETIC ACID; DIMERCAPROL; FARNESOL; FRUCTOSE 1,6 BISPHOSPHATE; GENISTEIN; GOSSYPOL; HYDRAZINE SULFATE; HYDROXYCITRIC ACID; KETOCONAZOLE; LITHIUM CHLORIDE; LONIDAMINE; MEPACRINE; METFORMIN; MILTEFOSINE; NICOTINIC ACID; OCTREOTIDE; QUININE; SILIBININ; SIMVASTATIN; SURAMIN; THIOCTIC ACID; TOLBUTAMIDE; UNINDEXED DRUG; XYLITOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BLADDER CANCER; CANCER RESEARCH; CANCER SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CONVULSION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG SCREENING; DRUG TARGETING; GASTROINTESTINAL HEMORRHAGE; IN VITRO STUDY; IN VIVO STUDY; LUNG CARCINOMA; LUNG SMALL CELL CANCER; MELANOMA; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; REPRODUCIBILITY; TREATMENT RESPONSE; WEIGHT REDUCTION;

EID: 84866609922     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-011-9692-7     Document Type: Article

References (47)

1. Warburg O. (1956) On the origin of cancer cells. Science 123:309-14
2. Robey RB, Hay N. (2009) Is Akt the "Warburg kinase"? Aktenergy metabolism interactions and oncogenesis. Sem Cancer Biol 10:25-31. doi:10.1016/j.semcancer.2008.11.010
3. Moreno-Sanchez R, Rodriguez-Enriquez S, Marin-Hernandez A, Saavedra E. (2007) Energy metabolism in tumor cells. FEBS J 274:1393-418. doi:10.1111/j.1742-4658.2007.05686.x
4. Vander Heiden MG, Cantley LC, Thompson CB. (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324:1029-33. doi:10.1126/science.1160809
5. Feron O. (2009) Pyruvate into lactate and back: from the Warburg effect to symbiotic energy fuel exchange in cancer cells. Radiother Oncol 92:329-33. doi:10.1016/j.radonc.2009.06.025
6. Kroemer G, Pouyssegur J. (2008) Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 13:472-82. doi:10.1016/j.ccr.2008.05.005
7. Altenberg B, Greulich KO. (2004) Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Genomics 84:1014-20. doi:10.1016/j.ygeno. 2004.08.010
8. Gatenby RA, Gillies RJ. (2004) Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4:891-9. doi:10.1038/nrc1478
9. Bui T, Thompson B. (2006) Cancer's sweet tooth. Cancer Cell 9:419-20. doi:10.1016/j.ccr.2006.05.012
10. Gatenby RA, Gawlinski ET, Gmitro AF, Kaylor B, Gillies RJ. (2006) Acid-mediated tumor invasion: a multidisciplinary study. Cancer Res 66:5216-23. doi:10.1158/0008-5472.CAN-05-4193
11. Yeung SJ, Pan J, Lee MH. (2008) Roles of p53, Myc and HIF-1 in regulating glycolysis-the seventh hallmark of cancer. Cell Mol Life Sci 65:3981-99
12. Pelicano H, Martin DS, Xu RH, Huang P. (2006) Glycolysis inhibition for anticancer treatment. Oncogene 25:4633-46. doi:10.1038/sj.onc.1209597
13. Michelakis ED, Sutendra G, Dromparis P, Webster L, Haromy A, Niven E, Maguire C, Gammer TL, Mackey JR, Fulton D, Abdulkarim B, McMurtry MS, et al. (2010) Metabolic modulation of glioblastoma with dichloroacetate. Sci Transl Med 2:31ra34. doi: 10.1126/scitranslmed.3000677
14. Berkson BM, Rubin DM, Berkson AJ. (2006) The long-term survival of a patient with pancreatic cancer with metastases to the liver after treatment with the intravenous alpha-lipoic acid/lowdose naltrexone protocol. Integr Cancer Ther 5:83-9. doi:10.1177/1534735405285901
15. Berkson BM, Rubin DM, Rubin AJ. (2009) Revisiting the ALA/N. (alpha-lipoic acid/low dose naltrexone) protocol for people with metastatic and nonmetastatic pancreatic cancer: a report of 3 new cases. Integr Cancer Ther 8:416-22. doi:10.1177/1534735409352082
16. Israël M, Schwartz L. (2005) Cancer as a Dysmethylation Syndrome. John Libbey, Paris
17. Israël M, Schwartz L. (2011) Carcinogenic mechanisms: anticancer drugs that target tumor metabolism. Biomedical Research 22. (2):130-164
18. Schwartz L, Abolhassani M, Guais A, Sanders E, Steyaert JM, Campion F, Israël M. (2010) A combination of alpha lipoic acid and calcium hydroxycitrate is efficient against mouse cancer models: preliminary results. Oncol Rep 23:1407-16. doi:10.3892/or-00000778
19. Korotchkina LG, Sidhu S, Patel MS. (2004) R-Lipoic acid inhibits mammalian pyruvate dehydrogenase kinase. Free Radic Res 38:1083-92. doi:10.1080/10715760400004168
20. Hatzivassiliou G, Zhao F, Bauer D, Andreadis C, Shaw AN, Dhanak D, Hingorani SR, Tuveson DA, Thompson CB. (2005) ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 8:311-1. doi:10.1016/j.ccr.2005.09.008
21. Food and Drug Administration, Center for Drug Evaluation and Research. (CDER). (2005) Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers, Pharmacology and Toxicology, July 2005.
22. Guais A, Baronzio GF, Sanders E, Campion F, Mainini C, Fiorentini G, Montagnani F, Behzadi M, Schwartz L, Abolhassani M. (2010) Adding a combination of hydroxycitrate and lipoic acid. (METABLOC™) to chemotherapy improves effectiveness against tumor development: experimental results and case report. Investig New Drugs In press 2010 Oct 8. [Epub ahead of print]. doi: 10.1007/s10637-010-9552-x
23. Tomayko MM, Reynolds CP. (1989) Determination of subcutaneous tumor size in athymic. (nude) mice. Cancer Chemother Pharmacol 24:148-54
24. Msaouel P, Galanis E, Koutsilieris M. (2009) Somatostatin and somatostatin receptors: implications for neoplastic growth and cancer biology. Expert Opin Investig Drugs 18:1297-316. doi:10.1517/13543780903176399
25. Prasad V, Fetscher S, Baum RP. (2007) Changing role of somatostatin receptor targeted drugs in NET: nuclear medicine's view. J Pharm Pharm Sci 10:321s-37s
26. Oberg K. (2010) Antitumor effect of octreotide LAR, a somatostatin analog. Nature Rev Endocrinol 6:188-9. doi:10.1038/nrendo.2010.3
27. Friedlander TW Weinberg VK Small EJ Sharib J Harzstark AL Lin AM Fong L Ryan CJ. (2010) Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II study. Urol Oncol In Press Sep 28. [Epub ahead of print]. doi:10.1016/j.urolonc. 2010.06.014
28. Grozinsky-Glasberg S, Shimon I, Korbonits M, Grossman AB. (2008) Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms. Endocr Relat Cancer 15:701, doi:10.1677/ERC-07-0288
29. Cerovac V, Monteserin-Garcia J, Rubinfeld H, Buchfelder M, Losa M, Florio T, Paez-Pereda M, Stalla GK, Theodroropoulou M. (2010) The somatostatin analogue octreotide confers sensitivity to rapamycin treatment on pituitary tumor cells. Cancer Res 70:666 doi:10.1158/0008-5472.CAN-09-2951
30. Sun Q, Chen X, Peng H, Wang F, Zha X, Wang Y, Jing Y, Yang H, Chen L, Zhang Y, Goto J, Onda H, Chen T, Wang MR, Lu Y, You H, Kwiatkowski D, Zhang H. (2011) Mammalian target of rapamycin up-regulation of pyruvate kinase isoeznzyme type M2 is critical for aerobic glycolysis and tumor growth. PNAS 108:4129-34. doi:10.1073/pnas.1014769108
31. Christofk HR, Vander Heiden MG, Harris MH, Rmanathan A, Gerszten RE, Wei R, Fleming MD, Schreiber SL, Cantley LC. (2008) The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452:230-3. doi:10.1038/nature06734
32. Pouessel D, Culine S, Guillot A, Di Stabile L, Thibaudeau E, Reymond D, Mottet N. (2008) Phase II study of TLN-232, a novel M2PK targeting agent administered by CIV to patients with advanced renal cell carcinoma. 33 rd ESMO Congress 12-16 September
33. Steták A, Veress R, Ovádi J, Csermely P, Kéri G, Ullrich A. (2007) Nuclear translocation of the tumor marker pyruvate kinase M2 induces programmed cell death. Cancer Res 67:1602-8. doi:10.1158/0008-5472.CAN- 06-2870
34. Szokolóczi O, Schwab R, Peták I, Orfi L, Pap A, Eberle AN, Szüts T, Kéril G. (2005) TT232, a novel signal transduction inhibitory compound in the therapy of cancer and inflammatory diseases. J Recept Signal Transduct Res 25(4-6):217-35
35. Oddstig J, Bernhardt P, Nilsson O, Ahlman H, Forssell-Aronsson E. (2006) Radiation-induced up-regulation of somatostatin receptor expression in small cell lung cancer in vitro. Nucl Med Biol 33:841-6. doi:10.1016/j.nucmedbio.2006. 07.010
36. Nayak TK, Atcher RW, Prossnitz ER, Norenberg JP. (2008) Enhancement of somatostatin-receptor-targeted. (177)Lu-[DOTA. (0)-Tyr[3]]-octreotide therapy by gemcitabine pretreatmentmediated receptor uptake, up-regulation and cell cycle modulation. Nucl Med Biol 35:673-8. doi:10.1016/j.nucmedbio.2008.05.003
37. Florio T. (2008) Molecular mechanisms of the antiproliferative activity of somatostatin receptors. (SSTRs) in neuroendocrine tumors. Front Biosci 13:822-40
38. Raderer M, Kurtaran A, Scheithauer W, Fiebiger W, Weinlaender G, Oberhuber G. (2001) Different response to the long-acting somatostatin analogues lanreotide and octreotide in a patient with a malignant carcinoid. Oncology 60:141-5
39. Rohaizak M, Farndon JR. (2002) Use of octreotide and lanreotide in the treatment of symptomatic non-resectable carcinoid tumors. ANZ J Surg 72:635-8. doi:10.1046/j.1445-2197.2002.02507.x
40. Hillman N, Herranz L, Alvarez C, Martínez Olmos MA, Márco A, Gómez-Pan A. (1998) Efficacy of octreotide in the regression of a metastatic carcinoid tumour despite negative imaging with In-111- pentetreotide. (Octreoscan). Exp Clin Endocrinol Diabetes 106:226-30. doi:10.1055/s-0029- 1211980
41. Jia WD, Xu GL, Wang W, Wang ZH, Li JS, Ma JL, Ren WH, Ge YS, Yu JH, Liu WB. (2009) A somatostatin analogue, octreotide, inhibits the occurrence of second primary tumors and lung metastasis after resection of hepatocellular carcinoma in mice. Tohoku J Exp Med 218:155-60. doi:10.1620/tjem.218.155
42. Ruessmann HJ. (2009) German Society of outpatient diabetes centers AND. (Arbeitsgemeinschaft niedergelassener diabetologisch tätiger Arzte e.V.): Switching from pathogenetic treatment with alpha-lipoic acid to gabapentin and other analgesics in painful diabetic neuropathy: a real-world study in outpatients. J Diabetes Complications 23:174-7
43. Moungjaroen J, Nimmannit U, Callery PS, Wang L, Azad N, Lipipun V, Chanvorachote P, Rojanasakul Y. (2006) Reactive oxygen species mediate caspace activation and apoptosis induced by lipoic acid in human lung epithelial cancer cells through Bcl-2 down regulation. J Pharmacol Exp Therapeut 319:1062-9. doi:10.1124/jpet.106.110965
44. Mantovani G, Macciò A, Madeddu C, Gramignano G, Serpe R, Massa E, Dessì M, Tanca FM, Sanna E, Deiana L, Panzone F, Contu P et al. (2008) Randomized phase III clinical trial of five different arms of treatment for patients with cancer cachexia: interim results. Nutrition 24:305-13. doi:10.1016/j.nut.2007.12.010
45. Shay KP, Moreau RF, Smith EJ, Smith AR, Hagen TM. (2009) Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. Biochim Biophys Acta 1790:1149-60. doi:10.1016/j.bbagen.2009.07.026
46. Kovacs EM, Westerterp-Plantenga MS. (2006) Effects of. (-)- hydroxycitrate on net fat synthesis as de novo lipogenesis. Physiol Behav 88:371-81. doi:10.1016/j.physbeh.2006.04.005
47. Ayuk J, Stewart SE, Stewart PM, Sheppard MC. (2002) Longterm safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly. J Clin Endocrinol Metab 87:4142-6